Very interesting point made by Ranjit Shahani from Novartis India: The immense talents in India's pharmaceutical companies should be focused on R&D of medicines that will help the people…
At Lacerta Bio, we've been reading the fascinating book, The Signal and The Noise by Nate Silver. The book is a terrific review of how and why forecasts often fail,…
The always excellent Bruce Booth wrote a good summary of the key Preclinical deals we've seen so far this year. The post is available here. Some of his broader questions are especially…
As BD consultants, we attend a number of conferences, both large and small. Some have one-on-one meetings, some don't. Some are scientific conferences, while others are focused on partnering. As…
Today we learn that generics giant Mylan has entered into a partnership with India-based Biocon to focus on insulin analog biosimilars: Under the terms of this collaboration, Mylan will have…
The announcement of the Allergan acquisition of MAP Pharmaceuticals for nearly $1 billion (and the NuPathe approval) is a good reminder of the potential value (both clinical and financial) of reformulation and drug…
Lacerta Bio, along with approximately 10,000 other life science investors, executives, consultants, service providers, hangers-on, and many others, congregated in San Francisco for a variety of conferences, including the JP…
Happy New Year! For many companies, 2012 was a challenging year. How will 2013 play out? Here are a few ideas we've discussed internally as we look forward to 2013:…
As we bring 2012 to a close, we're looking back at a few of the interesting events that took place. It was a challenge to whittle this down to a…
Consider the following situation: You are out-licensing an innovative asset in a niche therapeutic area It is a first-in-class molecule It has successfully demonstrated efficacy in two international Phase…